NeRRe Therapeutics CEO, Dr Mary Kerr, nominated to present at EBD Group’s BIO-Europe Spring 2018 conference, taking place March 12–14, 2018 in Amsterdam, Netherlands2018-04-132018-09-14https://www.nerretherapeutics.com/wp-content/uploads/2018/09/logo.pngNeRRe Therapeuticshttps://www.nerretherapeutics.com/wp-content/uploads/2018/09/logo.png200px200px
NeRRe Therapeutics CEO, Dr Mary Kerr, nominated to present at EBD Group’s BIO-Europe Spring 2018 conference, taking place March 12–14, 2018 in Amsterdam, Netherlands
NeRRe Therapeutics is a UK based clinical-stage company developing a unique portfolio of neurokinin (NK) receptor antagonists for the treatment of common debilitating conditions caused by neuronal hypersensitivity.